Abbas Hussain will take over as CEO of the Vifor Pharma Group on 16 August 2021 Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons St. Gallen,...

Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors Dividend of CHF 2.00 approved

Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed...

Topline data expected in the second half of 2021 St. Gallen, Switzerland, and Uniondale, NY, 29 April 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of...

CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is...

Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the first therapy available in Europe...

St. Gallen, Switzerland, 26 March 2021 – Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6...

FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVATM injection would be first therapy for treatment of pr uritus in hemodialysis patients...

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 Net sales up 3.7% at constant exchange rates (CER), despite significant...

Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board Dr Gianni Zampieriand Gilbert Achermann will not stand for re-election St. Gallen, Switzerland, 02 February 2021

As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from...

In its sixth year, a growing international coalition underlines significant harm to health caused by iron deficiency Impact on women moves up political agenda at REYKJAVÍK GLOBAL FORUM - WOMEN...

Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data Veltassa® will benefit from Fresenius Kabi’s...

Ferinject® significantly reduced the incidence of heart failure hospitalizations in patients with iron deficiency after acute heart failure Results of the AFFIRM-AHF trial support the use of...

Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is a first in class small-molecule hepatocyte growth factor (HGF) mimetic, addressing a...

Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal phase-III ADVOCATE trial of avacopan St...

Vifor Pharma secures US commercial rights for i.v. Korsuva in non-Fresenius Medical Care dialysis clinics representing approx. 66% of the market, under a profit-sharing arrangement with Cara Cara...

The study narrowly missed statistical significance on the primary endpoint Pre-specified adjustment of COVID-19 impact, the study showed a statistically significant advantage The totality of...

Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435 In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of...

St Gallen, September 1, 2020 – Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1,...

Net sales and EBITDA continued to grow in H1 2020 despite challenging market conditions due to COVID-19 Ferinject®/ Injectafer® demand impacted by global COVID-19 restrictions Sustained growth...

ST GALLEN, CH and MOUNTAIN VIEW, Calif., 18 May, 2020 – Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six...

Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Jacques Theurillat as new Chairman of the Board of Directors Etienne Jornod appointed...

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02)...

AGM will take place as planned on 14 May, 2020 under extraordinary conditions Shareholders are not allowed to attend in person and are requested to vote via independent proxy St Gallen, 31 March...